Impact Factor
3.70
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.99
656 total citations
h5-index
28
h5 depth signal
Cited share
86.2%
150 of 174
Total citations
656
Citation footprint
Metric signal
4.37
External metric anchor
Self-citation
1.4%
9 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
258
United States
151
United Kingdom
70
Italy
64
Germany
44
Citing Fields of Research
Allergies
233
Respiratory Support
207
Lung Cancer
142
Auto-Inflammatory Disorders
103
Cystic Fibrosis
62
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,044
Articles tracked across the journal lifetime
Indexed publication set
174
150 cited publications
Last 12 months
124
10.3 publications/month
Open access share
100.0%
124 OA publications in the last year
Leading citing country
China
258 citing publications
Leading citing field
Allergies
233 citing publications
Latest tracked publication
14 October 2026
10 recent records available
Coverage & Indexing History
v1n1, Oct. 2007-
v1n1, Oct. 2007-
Active Coverage
Research Focus & Classification
Indexed Subjects
Auto-Inflammatory Disorders
Allergies
Lung Cancer
Cystic Fibrosis
Respiratory Support
Broad Categories
Pulmonary Medicine
Therapeutics
Allergies
Auto-Inflammatory Disorders
Lung Cancer
Cystic Fibrosis
Respiratory Support
MeSH Descriptors
Respiratory System Agents
Respiratory Tract Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/17534666261488263
Open DOI
Nintedanib in progressive fibrosing hypersensitivity pneumonitis: Real-world effects on lung function and survival
Background: Fibrotic hypersensitivity pneumonitis (f-HP) may progress despite antigen avoidance and immunosuppressive therapy. Although nintedanib is approved for progressive pulmonary fibrosis (PPF), real-world evidence regarding its ef...
02
DOI 10.1177/17534666261495722
Open DOI
Rigid bronchoscopy using high-flow oxygenation and deep sedation: A feasibility, safety, and patient-reported tolerability survey
Background: Rigid bronchoscopy (RB) is conventionally performed under general anesthesia with jet or mechanical ventilation in an operating room and requires anesthesiologist support. Deep sedation with high-flow oxygenation (HFO), witho...
03
DOI 10.1177/17534666261497070
Open DOI
Individualising biologic therapy for paediatric severe asthma: A comparative review of all five approved agents, real-world evidence, and a biomarker-guided clinical decision algorithm
Severe asthma affects 5–10% of children with asthma yet accounts for disproportionate morbidity and healthcare utilisation. The recent expansion of biologic therapies—targeting IgE, IL-5, IL-4/13, TSLP, and IL-5 receptor α—has transforme...
04
DOI 10.1177/17534666251412733
Open DOI
Pulmonary fibrosis through patients’ eyes: an interpretative phenomenological analysis of illness perceptions and acceptance
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive, life-limiting lung disease that causes substantial morbidity. While there is growing recognition of the importance of symptom management and quality of life, little is kno...
05
DOI 10.1177/17534666261491576
Open DOI
Endoplasmic reticulum stress and maladaptive repair in fibrotic interstitial lung diseases: A human-evidence-based narrative review
Fibrotic interstitial lung diseases (ILDs) are characterized by progressive extracellular-matrix accumulation but arise from biologically diverse injuries. This narrative review examines endoplasmic reticulum (ER) stress as a context-dep...
06
DOI 10.1177/17534666261484754
Open DOI
Real-world analysis on hemodynamic effectiveness and adverse events of selexipag in pulmonary arterial hypertension
Background: Selexipag, an oral IP prostacyclin receptor agonist, improves outcomes in pulmonary arterial hypertension (PAH); however, real-world hemodynamic data and the relationship between adverse events (AEs) and treatment response ar...
07
DOI 10.1177/17534666261495482
Open DOI
Silent threat: A case report of acute fulminant exogenous lipoid pneumonia leading to severe ARDS
Exogenous lipoid pneumonia (ELP) is a rare pulmonary disorder resulting from the aspiration or inhalation of exogenous lipid substances. While most documented cases follow an indolent, chronic course and are associated with favorable out...
08
DOI 10.1177/17534666261493712
Open DOI
Novel hepatic function-based prognostic prediction model for pulmonary arterial hypertension
Background: Hepatic dysfunction is increasingly recognized as a contributor to adverse outcomes in patients with pulmonary arterial hypertension (PAH). However, current prognostic models for PAH do not incorporate hepatic function parame...
09
DOI 10.1177/17534666261493434
Open DOI
The diagnostic and prognostic role of MMP-1 and MMP-9 plasma concentrations in idiopathic pulmonary fibrosis
Background: Idiopathic pulmonary fibrosis (IPF) represents a chronic and irreversible progressive disease, while acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) represents a catastrophic event in the course of the disease wi...
10
DOI 10.1177/17534666261492547
Open DOI
Balloon pulmonary angioplasty for occlusive lesions of pulmonary artery in Takayasu arteritis: A cohort study
Background: Occlusive pulmonary arterial lesions represent a major technical challenge for balloon pulmonary angioplasty (BPA) in patients with Takayasu arteritis–associated pulmonary artery involvement. However, evidence and procedural ...
Bibliographical & Catalog Notes
Description based on first issue; title from cover.
Latest issue consulted: Vol. 1, no. 2 (Dec. 2007).
Also issued online.